Nirsevimab first potential immunisation to protect against RSV in infants
Synopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…
Synopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…
Synopsis : Valneva’s single-shot chikungunya vaccine candidate, VLA1553, offered a very high level of seroprotection in all adults, including the elderly. The…
Summary : The safety and efficacy of fezolinetant is being evaluated in the Phase III trial of over 1,800 women seeking relief…
Summary : Trodelvy® (sacituzumab govitecan-hziy) was found to significantly reduce the risk of disease progression or death in certain breast cancer patients. Trodelvy® (sacituzumab…
Highlight Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that Shionogi has…
Summary : 7th March 2022, Evonik has inaugurated the new Applied Technology Center in Americana (Brazil) aimed at developing modern and innovative sustainable solutions for…
Summary : With the registration of Syngenta’s PostivaTM fungicide, ornamental producers now have a powerful tool to assist manage challenging diseases like…
No Smoking Day is observed every year on the second Wednesday of March to let them know about the massive side effects…
Summary : Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility. Sanofi has…
Summary : Alterity Therapeutics have been granted a patent for compounds able to redistribute excess iron in the brain being developed as…